Rinderpest Virus Sequestration and Use in Posteradication Era - - Emerging Infectious Disease journal - CDC
Table of Contents
Volume 19, Number 1–January 2013
Dispatch
Rinderpest Virus Sequestration and Use in Posteradication Era
Abstract
After the 2011 declaration of rinderpest disease eradication, we surveyed 150 countries about rinderpest virus stocks. Forty-four laboratories in 35 countries held laboratory-attenuated strains, field strains, or diagnostic samples. Vaccine and reagent production and laboratory experiments continued. Rigorous standards are necessary to ensure that stocks are kept under safe conditions.Unintentional or deliberate virus release remains a serious concern as long as virus-containing material remains in the possession of vaccine manufacturers or research and diagnostic laboratories. An example to substantiate this concern is the last reported case of smallpox in a human, which originated from a laboratory (2). To manage the risk for rinderpest reintroduction, identifying these potential virus sources is essential. We conducted a questionnaire survey to assess the location and number of rinderpest virus stocks, their uses, and their storage conditions.
No hay comentarios:
Publicar un comentario